Cited 29 times in
Characterizing the outcomes of metastatic papillary renal cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2018-07-20T08:11:47Z | - |
dc.date.available | 2018-07-20T08:11:47Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160948 | - |
dc.description.abstract | Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | John Wiley & Sons Ltd. | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/pathology | - |
dc.subject.MESH | Clinical Trials as Topic | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Molecular Targeted Therapy/methods* | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Standard of Care | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Characterizing the outcomes of metastatic papillary renal cell carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | John Connor Wells | - |
dc.contributor.googleauthor | Frede Donskov | - |
dc.contributor.googleauthor | Anna P. Fraccon | - |
dc.contributor.googleauthor | Felice Pasini | - |
dc.contributor.googleauthor | Georg A. Bjarnason | - |
dc.contributor.googleauthor | Benoit Beuselinck | - |
dc.contributor.googleauthor | Jennifer J. Knox | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Neeraj Agarwal | - |
dc.contributor.googleauthor | Isaac Alex Bowman | - |
dc.contributor.googleauthor | Jae‐Lyun Lee | - |
dc.contributor.googleauthor | Sumanta K. Pal | - |
dc.contributor.googleauthor | Sandy Srinivas | - |
dc.contributor.googleauthor | Douglas Scott Ernst | - |
dc.contributor.googleauthor | Ulka N. Vaishampayan | - |
dc.contributor.googleauthor | Lori A. Wood | - |
dc.contributor.googleauthor | Robin Simpson | - |
dc.contributor.googleauthor | Guillermo De Velasco | - |
dc.contributor.googleauthor | Toni K. Choueiri | - |
dc.contributor.googleauthor | Daniel Y. C. Heng | - |
dc.identifier.doi | 10.1002/cam4.1048 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00449 | - |
dc.identifier.eissn | 2045-7634 | - |
dc.identifier.pmid | 28414866 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/cam4.1048 | - |
dc.subject.keyword | Metastatic renal cell carcinoma | - |
dc.subject.keyword | outcomes | - |
dc.subject.keyword | papillary | - |
dc.subject.keyword | response rate | - |
dc.subject.keyword | survival | - |
dc.subject.keyword | targeted therapy | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 6 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 902 | - |
dc.citation.endPage | 909 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, Vol.6(5) : 902-909, 2017 | - |
dc.identifier.rimsid | 60842 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.